P01.005 The impact of thrombocytopenia from concomitant and adjuvant temozolomide in patients with glioblastoma

BACKGROUND: Temozolomide (TMZ) administered daily with radiation therapy for six weeks, followed by adjuvant TMZ for six months is standard therapy for patients (pts) with newly diagnosed glioblastoma (GBM). Thrombocytopenia (TBP) usually appears in 10 % of patients and is responsible for treatment...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Nivet, A, Schernberg, A, Louvel, G, Dumont, S, Ammary, S, Rehalia-Blanchard, A, Clavère, P, Parker, F, Pallud, J, Dhermain, F
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Poster Presentations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144430/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.047
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia